Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274

1.

Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues.

Bonk S, Kluth M, Hube-Magg C, Polonski A, Soekeland G, Makropidi-Fraune G, Möller-Koop C, Witt M, Luebke AM, Hinsch A, Burandt E, Steurer S, Clauditz TS, Schlomm T, Perez D, Graefen M, Heinzer H, Huland H, Izbicki JR, Wilczak W, Minner S, Sauter G, Simon R.

Oncotarget. 2019 Sep 10;10(52):5439-5453. doi: 10.18632/oncotarget.27145. eCollection 2019 Sep 10.

2.

Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers.

Luebke AM, Attarchi-Tehrani A, Meiners J, Hube-Magg C, Lang DS, Kluth M, Tsourlakis MC, Minner S, Simon R, Sauter G, Büscheck F, Jacobsen F, Hinsch A, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Clauditz TS, Burandt E, Wilczak W, Höflmayer D.

Cancer Biol Med. 2019 May;16(2):319-330. doi: 10.20892/j.issn.2095-3941.2018.0384.

3.

Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy.

Schroeder C, Navid-Hill E, Meiners J, Hube-Magg C, Kluth M, Makrypidi-Fraune G, Simon R, Büscheck F, Luebke AM, Goebel C, Lang DS, Weidemann S, Neubauer E, Hinsch A, Jacobsen F, Lebok P, Michl U, Pehrke D, Huland H, Graefen M, Schlomm T, Sauter G, Höflmayer D.

Oncotarget. 2019 Aug 13;10(48):4973-4986. doi: 10.18632/oncotarget.27132. eCollection 2019 Aug 13.

4.

Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy.

Minner S, Hager D, Steurer S, Höflmayer D, Tsourlakis MC, Möller-Koop C, Clauditz TS, Hube-Magg C, Luebke AM, Simon R, Sauter G, Göbel C, Weidemann S, Lebok P, Dum D, Fraune C, Izbicki J, Burandt E, Schlomm T, Huland H, Heinzer H, Haese A, Graefen M, Heumann A.

Neoplasia. 2019 Sep;21(9):872-881. doi: 10.1016/j.neo.2019.07.003. Epub 2019 Aug 2.

5.

Analysis of the Effects of Day-Time vs. Night-Time Surgery on Renal Transplant Patient Outcomes.

Sugünes N, Bichmann A, Biernath N, Peters R, Budde K, Liefeldt L, Schlomm T, Friedersdorff F.

J Clin Med. 2019 Jul 18;8(7). pii: E1051. doi: 10.3390/jcm8071051.

6.

The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer.

Büscheck F, Zub M, Heumann A, Hube-Magg C, Simon R, Lang DS, Höflmayer D, Neubauer E, Jacobsen F, Hinsch A, Luebke AM, Tsourlakis MC, Sauter G, Huland H, Graefen M, Haese A, Heinzer H, Schlomm T, Clauditz TS, Burandt E, Wilczak W, Steurer S, Minner S.

Tumour Biol. 2019 Jul;41(7):1010428318824815. doi: 10.1177/1010428318824815.

PMID:
31296150
7.

Outcome of Photoselective Vaporization of the Prostate with the GreenLight-XPS 180 Watt System Compared to Transurethral Resection of the Prostate.

Reimann M, Fishman N, Lichy I, Wiemer L, Hofbauer S, Almedom Z, Buckendahl J, Steiner U, Schlomm T, Friedersdorff F, Cash H.

J Clin Med. 2019 Jul 10;8(7). pii: E1004. doi: 10.3390/jcm8071004.

8.

Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy.

Canter DJ, Freedland S, Rajamani S, Latsis M, Variano M, Halat S, Tward J, Cohen T, Stone S, Schlomm T, Bishoff J, Bardot S.

Prostate Cancer Prostatic Dis. 2019 Jun 27. doi: 10.1038/s41391-019-0159-9. [Epub ahead of print]

PMID:
31243337
9.

The gordian knots.

Schlomm T.

World J Urol. 2019 Jun 4. doi: 10.1007/s00345-019-02834-3. [Epub ahead of print] No abstract available.

PMID:
31165229
10.

Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy.

Klippenstein P, Schlomm T, von Amsberg G, Beyer B, Pompe RS, Michl U, Salomon G, Thederan I, Budäus L, Heinzer H, Tilki D, Haese A, Huland H, Graefen M, Steuber T, Tennstedt P.

Urol Oncol. 2019 Sep;37(9):575.e1-575.e7. doi: 10.1016/j.urolonc.2019.04.007. Epub 2019 Apr 30.

PMID:
31047783
11.

SNW1 is a prognostic biomarker in prostate cancer.

Höflmayer D, Willich C, Hube-Magg C, Simon R, Lang D, Neubauer E, Jacobsen F, Hinsch A, Luebke AM, Tsourlakis MC, Huland H, Graefen M, Haese A, Heinzer H, Minner S, Büscheck F, Sauter G, Schlomm T, Steurer S, Clauditz TS, Burandt E, Wilczak W, Bernreuther C.

Diagn Pathol. 2019 May 1;14(1):33. doi: 10.1186/s13000-019-0810-8.

12.

A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer.

Eichenauer T, Hussein M, Hube-Magg C, Kluth M, Büscheck F, Höflmayer D, Tsourlakis MC, Steurer S, Clauditz TS, Luebke AM, Burandt E, Wilczak W, Hinsch A, Dum D, Beyer B, Steuber T, Huland H, Graefen M, Simon R, Sauter G, Melling N, Schlomm T, Minner S.

Oncotarget. 2019 Mar 1;10(18):1729-1744. doi: 10.18632/oncotarget.26739. eCollection 2019 Mar 1.

13.

Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance.

Horak P, Weischenfeldt J, von Amsberg G, Beyer B, Schütte A, Uhrig S, Gieldon L, Klink B, Feuerbach L, Hübschmann D, Kreutzfeldt S, Heining C, Maier S, Hutter B, Penzel R, Schlesner M, Eils R, Sauter G, Stenzinger A, Brors B, Schröck E, Glimm H, Fröhling S, Schlomm T.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003657. doi: 10.1101/mcs.a003657. Print 2019 Apr.

14.

Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.

Schroeder C, Grell J, Hube-Magg C, Kluth M, Lang D, Simon R, Höflmayer D, Minner S, Burandt E, Clauditz TS, Büscheck F, Jacobsen F, Huland H, Graefen M, Schlomm T, Sauter G, Steurer S.

BMC Cancer. 2019 Mar 1;19(1):193. doi: 10.1186/s12885-019-5390-1.

15.

[The 2018 annual report on the 26th annual meeting of the working group for kidney transplantation of the German Society of Urology in Berlin].

Friedersdorff F, Putz J, Dreikorn K, Giessing M, Fornara P, Stöckle M, Schlomm T.

Urologe A. 2019 Mar;58(3):324-328. doi: 10.1007/s00120-019-0873-x. German. No abstract available.

PMID:
30762078
16.

5q21 deletion is often heterogeneous in prostate cancer.

Kluth M, Al Kilani Z, Özden C, Hussein K, Frogh S, Möller-Koop C, Burandt E, Steurer S, Büscheck F, Jacobsen F, Luebke AM, Minner S, Tsourlakis MC, Hoeflmayer D, Wittmer C, Schlomm T, Sauter G, Simon R, Wilczak W.

Genes Chromosomes Cancer. 2019 Aug;58(8):509-515. doi: 10.1002/gcc.22730. Epub 2019 Jan 24.

PMID:
30623509
17.

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J.

Cancer Cell. 2018 Dec 10;34(6):996-1011.e8. doi: 10.1016/j.ccell.2018.10.016.

PMID:
30537516
18.

Upregulation of centromere protein F is linked to aggressive prostate cancers.

Göbel C, Özden C, Schroeder C, Hube-Magg C, Kluth M, Möller-Koop C, Neubauer E, Hinsch A, Jacobsen F, Simon R, Sauter G, Michl U, Pehrke D, Huland H, Graefen M, Schlomm T, Luebke AM.

Cancer Manag Res. 2018 Nov 9;10:5491-5504. doi: 10.2147/CMAR.S165630. eCollection 2018.

19.

Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer.

Kluth M, Volta H, Hussein M, Taskin B, Frogh S, Möller-Koop C, Büscheck F, Jacobsen F, Tsourlakis MC, Lübke AM, Hinsch A, Clauditz T, Graefen M, Heinzer H, Huland H, Minner S, Sauter G, Wilczak W, Schlomm T, Simon R.

Cancer Manag Res. 2018 Nov 19;10:5909-5917. doi: 10.2147/CMAR.S172637. eCollection 2018.

20.

Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer.

Lange T, Oh-Hohenhorst SJ, Joosse SA, Pantel K, Hahn O, Gosau T, Dyshlovoy SA, Wellbrock J, Feldhaus S, Maar H, Gehrcke R, Kluth M, Simon R, Schlomm T, Huland H, Schumacher U.

Sci Rep. 2018 Dec 3;8(1):17535. doi: 10.1038/s41598-018-35695-8.

21.

A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.

Köcher S, Beyer B, Lange T, Nordquist L, Volquardsen J, Burdak-Rothkamm S, Schlomm T, Petersen C, Rothkamm K, Mansour WY.

Int J Cancer. 2019 Apr 1;144(7):1685-1696. doi: 10.1002/ijc.32018. Epub 2019 Jan 5.

PMID:
30478958
22.

Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.

Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis MC, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C.

Prostate. 2019 Feb;79(3):302-311. doi: 10.1002/pros.23736. Epub 2018 Nov 14.

PMID:
30430607
23.

High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases.

Brandi F, Grupp K, Hube-Magg C, Kluth M, Lang D, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wittmer C, Jacobsen F, Huland H, Steurer S, Lebok P, Hinsch A, Wilczak W, Schlomm T, Simon R.

Oncol Lett. 2018 Nov;16(5):6238-6244. doi: 10.3892/ol.2018.9417. Epub 2018 Sep 7.

24.

The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.

van Strijp D, de Witz C, Vos PC, den Biezen-Timmermans E, van Brussel A, Wrobel J, Baillie GS, Tennstedt P, Schlomm T, Heitkötter B, Huss S, Bögemann M, Houslay MD, Bangma C, Semjonow A, Hoffmann R.

Prostate Cancer. 2018 Jul 26;2018:5821616. doi: 10.1155/2018/5821616. eCollection 2018.

25.

Author Correction: Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.

Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang DS, Simon R, Beyer B, Thederan I, Sauter G, Izbicki JR, Luebke AM, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Schlomm T, Wilczak W.

Sci Rep. 2018 Aug 21;8(1):12821. doi: 10.1038/s41598-018-30975-9.

26.

[Reply to: PSA screening : Possible uses and harm by N. Keller, M. Jenny, G. Gigerenzer, R. Ablin].

Stephan C, Schlomm T, Jung K.

Urologe A. 2018 Jul;57(7):777-779. doi: 10.1007/s00120-018-0697-0. German. No abstract available.

PMID:
29926149
27.

13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer.

Kluth M, Scherzai S, Büschek F, Fraune C, Möller K, Höflmayer D, Minner S, Göbel C, Möller-Koop C, Hinsch A, Neubauer E, Tsourlakis MC, Sauter G, Heinzer H, Graefen M, Wilczak W, Luebke AM, Burandt E, Steurer S, Schlomm T, Simon R.

Genes Chromosomes Cancer. 2018 Oct;57(10):504-512. doi: 10.1002/gcc.22645. Epub 2018 Aug 20.

PMID:
29923647
28.

Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.

Wilczak W, Wittmer C, Clauditz T, Minner S, Steurer S, Büscheck F, Krech T, Lennartz M, Harms L, Leleu D, Ahrens M, Ingwerth S, Günther CT, Koop C, Simon R, Jacobsen F, Tsourlakis MC, Chirico V, Höflmayer D, Vettorazzi E, Haese A, Steuber T, Salomon G, Michl U, Budäus L, Tilki D, Thederan I, Fraune C, Göbel C, Henrich MC, Juhnke M, Möller K, Bawahab AA, Uhlig R, Adam M, Weidemann S, Beyer B, Huland H, Graefen M, Sauter G, Schlomm T.

Eur Urol. 2018 Sep;74(3):376-386. doi: 10.1016/j.eururo.2018.05.034. Epub 2018 Jun 13.

PMID:
29908878
29.

[PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection].

Kotzerke J, Böhmer D, Schlomm T, Maurer T, Beer AJ, Schmidberger H.

Nuklearmedizin. 2018 Jun;57(3):69-73. doi: 10.3413/Nukmed-2018030003. Epub 2018 Jun 5. German.

PMID:
29871008
30.

PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.

Heinrich MC, Göbel C, Kluth M, Bernreuther C, Sauer C, Schroeder C, Möller-Koop C, Hube-Magg C, Lebok P, Burandt E, Sauter G, Simon R, Huland H, Graefen M, Heinzer H, Schlomm T, Heumann A.

BMC Cancer. 2018 May 31;18(1):612. doi: 10.1186/s12885-018-4547-7.

31.

Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer.

Neubauer E, Latif M, Krause J, Heumann A, Armbrust M, Luehr C, Fraune C, Hube-Magg C, Kluth M, Möller-Koop C, Sauter G, Simon R, Beyer B, Pompe RS, Thederan I, Schlomm T, Büscheck F.

Exp Mol Pathol. 2018 Aug;105(1):50-56. doi: 10.1016/j.yexmp.2018.05.006. Epub 2018 May 24.

PMID:
29803408
32.

Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.

Pompe RS, Gild P, Karakiewicz PI, Bock LP, Schlomm T, Steuber T, Graefen M, Huland H, Tian Z, Tilki D.

Prostate. 2018 Jun;78(9):676-681. doi: 10.1002/pros.23511. Epub 2018 Mar 23.

PMID:
29570821
33.

Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram.

Pompe RS, Bandini M, Preisser F, Marchioni M, Zaffuto E, Tian Z, Salomon G, Schlomm T, Huland H, Graefen M, Tilki D, Shariat SF, Karakiewicz PI.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):386-393. doi: 10.1038/s41391-018-0033-1. Epub 2018 Feb 27.

PMID:
29487397
34.

Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer.

Hinsch A, Brolund M, Hube-Magg C, Kluth M, Simon R, Möller-Koop C, Sauter G, Steurer S, Luebke A, Angerer A, Wittmer C, Neubauer E, Göbel C, Büscheck F, Minner S, Wilczak W, Schlomm T, Jacobsen F, Clauditz TS, Krech T, Tsourlakis MC, Schroeder C.

World J Urol. 2018 Jun;36(6):877-882. doi: 10.1007/s00345-018-2225-7. Epub 2018 Feb 9.

PMID:
29427004
35.

Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer.

Kluth M, Jung S, Habib O, Eshagzaiy M, Heinl A, Amschler N, Masser S, Mader M, Runte F, Barow P, Frogh S, Omari J, Möller-Koop C, Hube-Magg C, Weischenfeldt J, Korbel J, Steurer S, Krech T, Huland H, Graefen M, Minner S, Sauter G, Schlomm T, Simon R.

Oncotarget. 2017 Nov 11;8(65):108923-108935. doi: 10.18632/oncotarget.22408. eCollection 2017 Dec 12.

36.

High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.

Heumann A, Heinemann N, Hube-Magg C, Lang DS, Grupp K, Kluth M, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Wittmer C, Jacobsen F, Huland H, Simon R, Schlomm T, Sauter G, Steurer S, Lebok P, Hinsch A.

BMC Cancer. 2018 Jan 5;18(1):37. doi: 10.1186/s12885-017-3956-3.

37.

PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort.

Lotan TL, Heumann A, Rico SD, Hicks J, Lecksell K, Koop C, Sauter G, Schlomm T, Simon R.

Oncotarget. 2017 Jul 10;8(39):65566-65576. doi: 10.18632/oncotarget.19217. eCollection 2017 Sep 12.

38.

FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.

Tsourlakis MC, Eleftheriadou A, Stender A, Weigand P, Grupp K, Hube-Magg C, Kluth M, Schroeder C, Steurer S, Hinsch A, Luebke A, Angerer A, Wittmer C, Friedrich E, Göbel C, Büscheck F, Heinzer H, Graefen M, Simon R, Sauter G, Wilczak W, Minner S, Schlomm T, Jacobsen F.

Carcinogenesis. 2017 Dec 7;38(12):1180-1187. doi: 10.1093/carcin/bgx105.

PMID:
29029032
39.

Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy.

Leyh-Bannurah SR, Karakiewicz PI, Dell'Oglio P, Briganti A, Schiffmann J, Pompe RS, Sauter G, Schlomm T, Heinzer H, Huland H, Graefen M, Budäus L.

Clin Genitourin Cancer. 2017 Aug 31. pii: S1558-7673(17)30246-X. doi: 10.1016/j.clgc.2017.08.005. [Epub ahead of print]

PMID:
28942009
40.

Mitochondrial mutations drive prostate cancer aggression.

Hopkins JF, Sabelnykova VY, Weischenfeldt J, Simon R, Aguiar JA, Alkallas R, Heisler LE, Zhang J, Watson JD, Chua MLK, Fraser M, Favero F, Lawerenz C, Plass C, Sauter G, McPherson JD, van der Kwast T, Korbel J, Schlomm T, Bristow RG, Boutros PC.

Nat Commun. 2017 Sep 22;8(1):656. doi: 10.1038/s41467-017-00377-y.

41.

High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.

Burdelski C, Shihada R, Hinsch A, Angerer A, Göbel C, Friedrich E, Hube-Magg C, Burdak-Rothkamm S, Kluth M, Simon R, Möller-Koop C, Sauter G, Büscheck F, Wittmer C, Clauditz TS, Krech T, Tsourlakis MC, Minner S, Graefen M, Schlomm T, Wilczak W, Jacobsen F.

Prostate. 2017 Nov;77(15):1528-1538. doi: 10.1002/pros.23431. Epub 2017 Sep 19.

PMID:
28929505
42.

Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.

Jacobsen F, Kraft J, Schroeder C, Hube-Magg C, Kluth M, Lang DS, Simon R, Sauter G, Izbicki JR, Clauditz TS, Luebke AM, Hinsch A, Wilczak W, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Melling N.

Neoplasia. 2017 Sep;19(9):707-715. doi: 10.1016/j.neo.2017.06.003. Epub 2017 Aug 19.

43.

Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study.

Steuber T, Berg KD, Røder MA, Brasso K, Iversen P, Huland H, Tiebel A, Schlomm T, Haese A, Salomon G, Budäus L, Tilki D, Heinzer H, Graefen M, Mandel P.

Eur Urol Focus. 2017 Dec;3(6):646-649. doi: 10.1016/j.euf.2017.06.016. Epub 2017 Jul 8.

PMID:
28753877
44.

Incidence, Risk Factors, Management, and Complications of Rectal Injuries During Radical Prostatectomy.

Mandel P, Linnemannstöns A, Chun F, Schlomm T, Pompe R, Budäus L, Rosenbaum C, Ludwig T, Dahlem R, Fisch M, Graefen M, Huland H, Tilki D, Steuber T.

Eur Urol Focus. 2018 Jul;4(4):554-557. doi: 10.1016/j.euf.2017.01.008. Epub 2017 Feb 7.

PMID:
28753847
45.

Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.

Alves de Inda M, van Strijp D, den Biezen-Timmermans E, van Brussel A, Wrobel J, van Zon H, Vos P, Baillie GS, Tennstedt P, Schlomm T, Houslay MD, Bangma C, Hoffmann R.

Eur Urol Focus. 2018 Apr;4(3):376-384. doi: 10.1016/j.euf.2017.05.010. Epub 2017 Jun 13.

46.

Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer.

Jacobsen F, Taskin B, Melling N, Sauer C, Wittmer C, Hube-Magg C, Kluth M, Simon R, Pehrke D, Beyer B, Steuber T, Thederan I, Sauter G, Schlomm T, Wilczak W, Möller K, Weidemann SA, Burdak-Rothkamm S.

BMC Cancer. 2017 Jul 26;17(1):504. doi: 10.1186/s12885-017-3489-9.

47.

Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.

Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG.

Cell Rep. 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049.

48.

Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.

Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang DS, Simon R, Beyer B, Thederan I, Sauter G, Izbicki JR, Luebke AM, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Schlomm T, Wilczak W.

Sci Rep. 2017 May 17;7(1):2056. doi: 10.1038/s41598-017-02279-x. Erratum in: Sci Rep. 2018 Aug 21;8(1):12821.

49.

Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.

Tosoian JJ, Chappidi MR, Bishoff JT, Freedland SJ, Reid J, Brawer M, Stone S, Schlomm T, Ross AE.

BJU Int. 2017 Dec;120(6):808-814. doi: 10.1111/bju.13911. Epub 2017 Jun 11.

50.

Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion.

Juhnke M, Heumann A, Chirico V, Höflmayer D, Menz A, Hinsch A, Hube-Magg C, Kluth M, Lang DS, Möller-Koop C, Sauter G, Simon R, Beyer B, Pompe R, Thederan I, Schlomm T, Luebke AM.

Mol Carcinog. 2017 Sep;56(9):2135-2145. doi: 10.1002/mc.22670. Epub 2017 May 22.

PMID:
28467610

Supplemental Content

Loading ...
Support Center